Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
625.73K | 403.53K | 132.77K | 11.34K | 0.00 | 0.00 | Gross Profit |
372.07K | 206.42K | 100.63K | 5.04K | -47.57K | -51.84K | EBIT |
-18.88M | ― | -16.12M | -16.05M | -11.67M | -13.02M | EBITDA |
-15.46M | -17.92M | -11.72M | -15.95M | -6.11M | -7.01M | Net Income Common Stockholders |
-15.50M | -18.94M | -3.59M | -16.76M | -8.00M | -10.50M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
1.21M | 18.43M | 28.44M | 5.14M | 11.70M | 1.21M | Total Assets |
2.55M | 27.09M | 34.60M | 9.98M | 13.16M | 2.55M | Total Debt |
14.21M | 192.89K | 325.68K | 441.17K | 400.81K | 14.21M | Net Debt |
13.00M | -18.18M | -28.11M | -4.28M | -9.62M | 13.00M | Total Liabilities |
19.03M | 7.10M | 8.49M | 2.56M | 2.40M | 19.03M | Stockholders Equity |
-16.47M | 15.06M | 26.11M | 7.42M | 10.76M | -16.47M |
Cash Flow | Free Cash Flow | ||||
-16.01M | -15.17M | -13.86M | -16.03M | -8.26M | -5.83M | Operating Cash Flow |
-15.64M | -14.70M | -11.87M | -13.91M | -8.26M | -5.79M | Investing Cash Flow |
48.01K | 206.01K | -1.75M | -1.45M | 7.24M | -46.95K | Financing Cash Flow |
7.07M | 234.47K | 40.28M | 10.06M | 9.84M | 5.20M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
59 Neutral | C$105.13M | ― | -8.34% | ― | 0.69% | -95.27% | |
55 Neutral | C$23.81M | ― | -23.87% | ― | 18.97% | 17.57% | |
54 Neutral | C$219.39M | ― | -66.14% | ― | 51.21% | 15.33% | |
53 Neutral | $5.20B | 3.32 | -45.04% | 2.84% | 16.81% | -0.31% | |
50 Neutral | C$24.31M | ― | -163.62% | ― | 113.85% | 11.38% | |
49 Neutral | C$52.03M | ― | -291.48% | ― | -8.63% | 7.04% | |
44 Neutral | C$17.95M | ― | 207.08% | ― | 280.56% | -7.28% |
Perimeter Medical Imaging AI announced that HonorHealth is the first healthcare system in Arizona to implement its S-Series OCT technology, enhancing surgical decision-making with real-time, high-resolution imaging of tissue margins. This deployment marks a significant step in Perimeter’s nationwide expansion, increasing access to their technology in a major metropolitan area and reflecting the growing demand for improved surgical outcomes.
Spark’s Take on TSE:PINK Stock
According to Spark, TipRanks’ AI Analyst, TSE:PINK is a Neutral.
Perimeter Medical Imaging AI shows strong revenue growth and promising developments in product approval, positioning it for future expansion. However, persistent net losses, cash flow issues, and bearish technical trends pose significant challenges. The stock’s valuation is unattractive due to negative profitability. While the company is in a pivotal growth phase with potential regulatory milestones ahead, financial and operational hurdles must be overcome to enhance investor confidence.
To see Spark’s full report on TSE:PINK stock, click here.
Perimeter Medical Imaging AI announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference, where it will present updates on its business. This participation underscores Perimeter’s ongoing efforts to enhance its industry presence and communicate its technological advancements, potentially impacting its market positioning and stakeholder engagement.
Spark’s Take on TSE:PINK Stock
According to Spark, TipRanks’ AI Analyst, TSE:PINK is a Neutral.
Perimeter Medical Imaging AI shows strong revenue growth and promising developments in product approval, positioning it for future expansion. However, persistent net losses, cash flow issues, and bearish technical trends pose significant challenges. The stock’s valuation is unattractive due to negative profitability. While the company is in a pivotal growth phase with potential regulatory milestones ahead, financial and operational hurdles must be overcome to enhance investor confidence.
To see Spark’s full report on TSE:PINK stock, click here.
Perimeter Medical Imaging AI, Inc. announced a proposed public offering of units, consisting of common shares and purchase warrants, to raise funds for the commercialization of its technology, clinical evidence establishment, and product development. The offering, expected to close by the end of April 2025, will be conducted on a ‘best efforts’ basis with A.G.P. Canada Investments ULC as the agent, and aims to strengthen the company’s market position and operational capabilities.
Perimeter Medical Imaging AI reported significant financial growth in 2024, with a 303% increase in Q4 revenues compared to the previous year, driven by the adoption of its S-Series OCT systems. The company is advancing its B-Series OCT system, having successfully completed a pivotal trial for breast-conserving surgeries and submitted a PMA application to the FDA. This progress positions Perimeter for further expansion and potential regulatory approval, which could enhance its market position and impact stakeholders positively.
Perimeter Medical Imaging AI announced it will release its fourth quarter and full year 2024 financial results on March 26, 2025, followed by a conference call to discuss the outcomes and provide a corporate update. This announcement is significant as it may impact the company’s operations and industry positioning, especially considering its ongoing clinical trials and the potential market introduction of its next-generation imaging technology.
Perimeter Medical Imaging AI has submitted a Premarket Approval application to the FDA for its B-Series OCT system with ImgAssist AI 2.0, aimed at improving outcomes in breast-conserving surgeries. The pivotal trial showed significant results in reducing residual cancer during surgery, suggesting potential widespread adoption among breast cancer surgeons if approved, marking a significant milestone for the company’s operations and industry positioning.
Perimeter Medical Imaging AI announced that its pivotal trial results for the B-Series OCT with ImgAssist AI 2.0 will be presented at the 2025 Annual Meeting of the American Society of Breast Surgeons. The trial showed a statistically significant reduction in residual cancer during surgery, supporting the company’s efforts to gain FDA approval for their next-generation imaging system. This development could enhance the adoption of their technology, providing surgeons with improved tools for breast cancer surgery.
Perimeter Medical Imaging AI announced that its common shares will begin trading on the OTCQX Best Market, enhancing its visibility and efforts to expand its U.S. shareholder base. This move follows positive results from a pivotal study supporting the company’s FDA premarket approval submission for its B-Series OCT with ImgAssist AI, which demonstrated significant improvements in surgical outcomes, potentially reducing the need for reoperations.